RVXoldtimer, thanks for the refresher and I do recall everything you posted. Yes, I was swept up with great hope and I was counting on something really significant (CVR or a full buy out) of ZE or even ZCC and a top line of BoM in January given the 3rd Eye commitment due Jan 31.

So I am very disappointed but looking back on it and Don I am not surprised. Still, the peanut is inching forward and hopefully we'll see strong BoM results in Sept but I'm going to be cautious even on that. I really hope the analyse some cross tabs and bring some spice to the announcement.

It often strikes me that there must be a tremendous gap between Don's view of things like trial status and the view of the clinical trial management team. But that is behind us.

Thanks RVXoldtimer for your helpful posts and insights.

GLTA

Toinv